About CLINUVEL

Corporate News & Publications

CLINUVEL's company releases, including archives.

Annual Report for the year ended 30 June 2007
Wednesday, 27 June 2007 15:00

Open Briefing®. CLINUVEL. Update on Start of Phase III

Open Briefing®. CLINUVEL. Update on Start of Phase III
Thursday, 07 June 2007 09:00

Appendix 3Z - Final Directors Interest Notice

Appendix 3Z - Final Director’s Interest Notice
Wednesday, 06 June 2007 09:00

Appendix 3B - Application for Quotation of Additional Securities

Appendix 3B - Application for Quotation of Additional Securities
CLINUVEL starts multicentre Phase III trial in Erythropoietic Protoporphyria ahead of schedule First EPP patients have been administered CUV1647 at Triemli Hospital, ZÏ‹rich, Switzerland Interim results to follow mid 2008 Pending results CLINUVEL may seek orphan drug status for CUV1647 This EPP trial represents the second Phase III trial of CUV1647 to begin in 2007 Melbourne, Australia June 5th, 2007 CLINUVEL Pharmaceuticals Limited (ASX: CUV, XETRA-DAX:UR9) is pleased to announce that the Phase III trial of CUV1647 in Erythropoietic Protoporphyria (EPP - absolute sun intolerance) has begun ahead of schedule, in ZÏ‹rich Switzerland. CLINUVEL’s CEO, Dr Philippe Wolgen said: “This…
Thursday, 31 May 2007 16:00

CLINUVEL board member resigns

CLINUVEL board member resigns
Thursday, 31 May 2007 16:00

CLINUVEL Share Purchase Plan completed

CLINUVEL Share Purchase Plan completed
Monday, 21 May 2007 10:00

Tolhurst Noall - update

Tolhurst Noall - update
CLINUVEL Pharmaceuticals Limited (ASX:CUV, XETRA-DAX:UR9) is pleased to announce that the Phase III trial of CUV1647 in Polymorphic Light Eruption (PLE/PMLE) has begun in Europe. The first group of patients has received either the active implant containing photo-protective CUV1647 or a placebo implant. This Phase III multicentre, randomised, double blind, placebo controlled study follows the Phase II results from August 2006 in which CUV1647 significantly reduced the need for rescue medication, in the form of steroids or anti-inflammatory drugs, in PLE patients. The Phase III trial will further determine whether CUV1647 can prevent or reduce the severity of symptoms in…
Thursday, 10 May 2007 16:00

CLINUVEL Share Purchase Plan

CLINUVEL Share Purchase Plan